ImmuCell Corporation (ICCC) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysten schätzen Gewinn pro Aktie (EPS) von $-0.11 und Umsatz von $0.02B für das nächste Geschäftsjahr.
Gewinn pro Aktie (EPS) Erfolgsbilanz: 2024: tatsächlich $-0.26 vs Schätzung $-0.11 (verfehlt -136.4%). 2025: tatsächlich $-0.12 vs Schätzung $-0.24 (übertroffen +50%). Analysten-Genauigkeit: 21%.
GpA-Schätzungen — ICCC
21%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.26
vs Est –$0.11
▼ 57.7% off
2025
Actual –$0.12
vs Est –$0.24
▲ 100.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Umsatzschätzungen — ICCC
64%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.026B
vs Est $0.019B
▲ 27.5% off
2025
Actual $0.028B
vs Est $0.015B
▲ 45.2% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
